SPAS(SH:603168) Xin Lang Cai Jing·2025-11-21 02:56Company Overview - Zhejiang Shapuaisi Pharmaceutical Co., Ltd. is located in Pinghu City, Zhejiang Province, and was established on July 17, 2000. The company went public on July 2, 2014. Its main business includes the research, production, and sales of eye drops, large-volume injections, and cefuroxime, with revenue composition as follows: 65.84% from product sales, 29.11% from medical services, and 5.05% from other sources [1]. Stock Performance - On November 21, Shapuaisi's stock price fell by 5.04%, closing at 7.72 CNY per share, with a trading volume of 28.37 million CNY and a turnover rate of 0.96%. The total market capitalization is 2.888 billion CNY. The stock has experienced a continuous decline for four days, with a cumulative drop of 4.13% during this period [1]. Shareholder Information - Among the top ten circulating shareholders of Shapuaisi, the Yuanxin Yongfeng Fund has a fund that entered the top ten in the third quarter, holding 2.894 million shares, which accounts for 0.9% of the circulating shares. The estimated floating loss today is approximately 1.1865 million CNY, with a floating loss of 1.0129 million CNY during the four-day decline [2]. Fund Performance - Yuanxin Yongfeng Medical Health A (006274) was established on November 29, 2018, with a current scale of 387 million CNY. Year-to-date returns are 37.08%, ranking 1688 out of 8136 in its category, while the one-year return is 28.45%, ranking 2260 out of 8056. Since its inception, the fund has achieved a return of 131.51% [2]. Fund Manager Information - The fund manager of Yuanxin Yongfeng Medical Health A is Xiao Shiyuan, who has a cumulative tenure of 8 years and 156 days. The total asset scale under his management is 2.272 billion CNY, with the best fund return during his tenure being 137.33% and the worst being 21.37% [2].